新開源(300109.SZ):擬將精細化工業務相關的主要資產及負債劃轉至子公司新開源製藥
格隆匯12月28日丨新開源(300109.SZ)公佈,公司於2021年12月26日召開第四屆董事會第三十七次會議和第四屆監事會第十七次會議審議通過了《關於向全資子公司劃轉資產的議案》,擬將公司精細化工業務相關的主要資產及負債劃轉至全資子公司博愛新開源製藥有限公司(“新開源製藥”)。
為明晰集團總部與下屬各子公司的目標與責任,實現生產經營職能與集團管理職能相分離,公司擬以2021年12月31日為劃轉基準日向全資子公司新開源製藥劃轉精細化工業務相關的資產及負債。此次擬劃轉的總資產約為91664.39萬元,總負債約為45565.29萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.